Search Results for "drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for drug. Results 1371 to 1380 of 2586 total matches.

Crisaborole (Eucrisa) for Atopic Dermatitis

   
The Medical Letter on Drugs and Therapeutics • Feb 27, 2017  (Issue 1515)
Topical Nonsteroidal Drugs for Atopic Dermatitis Drug Cost1 Calcineurin Inhibitors Pimecrolimus 1 ...
The FDA has approved crisaborole 2% ointment (Eucrisa – Pfizer) for topical treatment of mild to moderate atopic dermatitis in patients ≥2 years old. It is the first phosphodiesterase type-4 (PDE4) inhibitor to be approved in the US for this indication.
Med Lett Drugs Ther. 2017 Feb 27;59(1515):34-5 |  Show IntroductionHide Introduction

Aducanumab (Aduhelm) for Alzheimer's Disease

   
The Medical Letter on Drugs and Therapeutics • Jul 12, 2021  (Issue 1628)
for the drug alone. Aducanumab-avwa (Aduhelm – Biogen/Eisai), an IV amyloid beta-directed monoclonal antibody ...
Aducanumab-avwa (Aduhelm – Biogen/Eisai), an IV amyloid beta-directed monoclonal antibody, has received accelerated approval from the FDA for treatment of Alzheimer's disease. The approval was based on the surrogate endpoint of reduction in amyloid beta plaques in the brain. The manufacturer is required to conduct an additional randomized controlled trial to establish that reducing amyloid beta plaques with aducanumab improves clinical outcomes in patients with Alzheimer's disease.
Med Lett Drugs Ther. 2021 Jul 12;63(1628):105-6 |  Show IntroductionHide Introduction

Difelikefalin (Korsuva) for Chronic Kidney Disease-Associated Pruritus

   
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022  (Issue 1643)
. It is the first drug to be approved for this indication and the first KOR agonist to become available ...
Difelikefalin (Korsuva – Vifor), an IV kappa opioid receptor (KOR) agonist, has been approved by the FDA for treatment of moderate to severe pruritus associated with chronic kidney disease (CKD) in adults on hemodialysis. It is the first drug to be approved for this indication and the first KOR agonist to become available in the US. Difelikefalin has not been studied in patients on peritoneal dialysis.
Med Lett Drugs Ther. 2022 Feb 7;64(1643):18-9 |  Show IntroductionHide Introduction

Polatuzumab vedotin (Polivy) for Lymphoma (online only)

   
The Medical Letter on Drugs and Therapeutics • May 29, 2023  (Issue 1677)
) in adults who have an International Prognostic Index (IPI) score ≥2. The drug was previously approved ...
Polatuzumab vedotin-piiq (Polivy – Genentech), a CD79b-directed antibody and microtubule inhibitor conjugate, has been approved by the FDA for use in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for first-line treatment of diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL) in adults who have an International Prognostic Index (IPI) score ≥2. The drug was previously approved for use in combination with bendamustine and rituximab for treatment of patients with relapsed or refactory DLBCL,...
Med Lett Drugs Ther. 2023 May 29;65(1677):e89-90   doi:10.58347/tml.2023.1677f |  Show IntroductionHide Introduction

Asciminib (Scemblix) for Chronic Myeloid Leukemia (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023  (Issue 1678)
aminotransferase, lipase, and amylase levels. DRUG INTERACTIONS — Asciminib is a substrate and inhibitor ...
Asciminib (Scemblix – Novartis), an oral kinase inhibitor, has been approved by the FDA for treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with ≥2 tyrosine kinase inhibitors and for adults with Ph+ CML in CP with a T315I mutation.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e107-8   doi:10.58347/tml.2023.1678g |  Show IntroductionHide Introduction

Relugolix (Orgovyx) for Advanced Prostate Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 24, 2023  (Issue 1681)
leuprolide.3 1. Degarelix (Firmagon) for prostate cancer. Med Lett Drugs Ther 2009; 51:82. 2. TS Thomas ...
The oral gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix (Orgovyx – Myovant Sciences/Pfizer) has been approved by the FDA for treatment of advanced prostate cancer in adults. It is the first oral GnRH receptor antagonist to become available in the US; degarelix (Firmagon), an injectable GnRH receptor antagonist, has been available since 2008 for the same indication.
Med Lett Drugs Ther. 2023 Jul 24;65(1681):e121-2   doi:10.58347/tml.2023.1681e |  Show IntroductionHide Introduction

Tepotinib (Tepmetko) for NSCLC (online only)

   
The Medical Letter on Drugs and Therapeutics • Apr 29, 2024  (Issue 1701)
patients who received the drug, the objective response rate (ORR) was 51.4% and the median duration ...
The FDA has granted regular approval to the oral kinase inhibitor tepotinib (Tepmetko – EMD Serono) for treatment of adults with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. MET exon 14 skipping mutations occur in 3-4% of NSCLC cases and are associated with advanced disease and a poor prognosis. Tepotinib received accelerated approval for the same indication in 2021 based on initial overall response rates and duration of response.
Med Lett Drugs Ther. 2024 Apr 29;66(1701):e73-4   doi:10.58347/tml.2024.1701f |  Show IntroductionHide Introduction

In Brief: Pembrolizumab (Keytruda) for Cancers with Biomarkers (online only)

   
The Medical Letter on Drugs and Therapeutics • Jan 01, 2018  (Issue 1537)
with a fluoropyrimidine, oxaliplatin, and irinotecan. This is the first approval of a cancer drug based solely ...
The immune checkpoint inhibitor pembrolizumab (Keytruda – Merck), a programmed death receptor-1 (PD-1) inhibitor, has been granted accelerated approval by the FDA for use in adults and children who have unresectable or metastatic microsatellite-instability-high (MSI-H) or mismatch-repair-deficient (dMMR) solid tumors that have progressed following treatment, and do not have any satisfactory alternative treatment options. For metastatic colorectal cancer, the indication is limited to tumors that have progressed following combination treatment with a fluoropyrimidine, oxaliplatin, and...
Med Lett Drugs Ther. 2018 Jan 1;60(1537):e8 |  Show IntroductionHide Introduction

In Brief: Wezlana — An Ustekinumab Biosimilar Interchangeable with Stelara

   
The Medical Letter on Drugs and Therapeutics • Jul 22, 2024  (Issue 1707)
of the drug is not yet available, but will presumably be less expensive than Stelara. The wholesale ...
The FDA has approved ustekinumab-auub (Wezlana – Amgen), an interchangeable biosimilar product similar to the interleukin-12 and -23 antagonist Stelara, for treatment of the same indications as Stelara (see Table 1). Wezlana is the first Stelara biosimilar to be approved in the US.
Med Lett Drugs Ther. 2024 Jul 22;66(1707):119   doi:10.58347/tml.2024.1707e |  Show IntroductionHide Introduction

In Brief: Lisdexamfetamine (Vyvanse) for Binge Eating Disorder

   
The Medical Letter on Drugs and Therapeutics • Mar 16, 2015  (Issue 1464)
The Medical Letter® on Drugs and Therapeutics Objective Drug Reviews Since 1959 Volume 57 (Issue ...
Lisdexamfetamine dimesylate (Vyvanse), a prodrug of dextroamphetamine previously approved for treatment of attention-deficit/hyperactivity disorder, has now been approved for treatment of moderate-to-severe binge eating disorder (recurrent episodes of compulsive overeating without purging) in adults.FDA approval of lisdexamfetamine for this indication was based on two unpublished, 12-week trials, summarized in the package insert, that randomized patients with moderate-to-severe binge eating disorder to lisdexamfetamine 30 mg/day, which was titrated to 50 mg or, if needed, 70 mg, or to placebo....
Med Lett Drugs Ther. 2015 Mar 16;57(1464):42 |  Show IntroductionHide Introduction